Drug news
FDA Advisory Committee rejects Zohydro for Chronic Pain treatment
The FDA Anasthetic and Analgesic Advisory Committee found Zohydro (hydrocodone bitartrate extended-release capsules)from Zogenix, was effective in managing Moderate to Severe Pain when a continuous round -the -clock opioid analgesic is needed but was not comfortable with the lack of an abuse deterrent mechanism and voted 11-2 to reject the drug.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins